DigestRedComo funciona
Red
/
Empresas
Za
No verificado

Zai Lab Limited

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaOncologíaSalud

65 Comunicados de prensa

Ver todos los comunicados de prensa
22/04/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
VIH, SIDA y enfermedades autoinmunes
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
Fuente
Zai Lab Limited
Editor
Business Wire
1.00
0
18/04/2026
Eventos
Industria
Salud
Sanidad
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
Fuente
Zai Lab Limited
Editor
Business Wire
1.00
0
17/04/2026
Eventos
Industria
Web y redes sociales
Telefonía
Higiene alimentaria
Medicina - Varios
Biotecnología
Medicina nuclear
Salud
Farmacéutica
Sanidad
Oncología
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
Fuente
Zai Lab Limited
Editor
Business Wire
1.00
0
01/04/2026
Mercado laboral
Industria
Oncología
Salud
Medicina - Varios
Medicina nuclear
Farmacéutica
Biotecnología
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Fuente
Zai Lab Limited
Editor
Business Wire
1.00
0
17/03/2026
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
Eventos
Industria
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
Fuente
Zai Lab Limited
Editor
Business Wire
1.00
0
26/02/2026
Web y redes sociales
Telefonía
Mercado de valores
Oncología
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Farmacéutica
Biotecnología
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
Fuente
Zai Lab Limited
Editor
Business Wire
1.00
0
10/02/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
VIH, SIDA y enfermedades autoinmunes
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
Fuente
Zai Lab Limited
Editor
Business Wire
1.00
0
13/01/2026
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
Fuente
Zai Lab Limited
Editor
Business Wire
1.00
0
06/01/2026
Salud
Higiene alimentaria
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
Fuente
Zai Lab Limited
Editor
Business Wire
1.00
0
05/01/2026
Eventos
Web y redes sociales
VIH, SIDA y enfermedades autoinmunes
Salud
Farmacéutica
Oncología
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
Fuente
Zai Lab Limited
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0